• Ep 11. Psoriasis Part 2: Psoriatic Arthritis, Topicals, Systemics, Biologics, and More
    2026/10/05

    Send us Fan Mail

    Psoriasis Part 2: Differentials, Psoriatic Arthritis Screening, and the Psoriasis Treatment Ladder | The Derm Resident

    Contact: thedermresident.pod@gmail.com

    Hosts Dr. Jonny Hatch and Dr. Deven Curtis continue psoriasis with a focus on chronic plaque differentials, psoriatic arthritis, and a practical treatment ladder. They review mimickers including seborrheic dermatitis and lichen simplex chronicus (including “sebo-psoriasis”), mycosis fungoides prompting biopsy when plaques are treatment-resistant or atrophic, hypertrophic lichen planus on shins, and guttate-pattern differentials such as pityriasis rosea, pityriasis lichenoides chronica, and secondary syphilis. They emphasize screening for psoriatic arthritis (about one-third of patients; HLA-B27 association) using joint/back pain history, nail findings, and dactylitis, with rheumatology referral when appropriate. Treatments covered include topical steroids by site, calcipotriene, tazarotene, roflumilast foam, tapinarof, phototherapy (narrowband UVB preferred over PUVA), and systemic therapies (methotrexate with folate, cyclosporine, apremilast, acitretin) plus biologics (TNF, IL-17, IL-23, ustekinumab) and deucravacitinib, along with biologic prescreening (TB, hepatitis, CBC/CMP, vaccine counseling) and psoriasis comorbidity risks.

    00:00 Show Intro and Disclaimer
    00:29 Plaque Psoriasis Differentials
    02:21 Guttate Mimickers
    03:25 Screening for Psoriatic Arthritis
    04:53 Topical Treatment Basics
    06:32 Nonsteroid Topicals and New Agents
    08:13 Phototherapy UVB and PUVA
    10:45 Systemics Methotrexate Deep Dive
    13:45 Cyclosporine and Oral Options
    18:11 Biologics TNF Alpha Inhibitors
    22:41 IL-17 Inhibitors Key Pearls
    25:47 IL-23 and IL-12/23 Therapies
    28:23 Deucravacitinib and Biologic Workup
    30:46 Psoriasis as Systemic Disease
    31:32 Closing Pearls and Wrap Up

    This episode is sponsored by Mind the Skin, a patent-pending, steroid-free, patch system. Learn more at mindtheskinlabs.com. Use code TDRP26 at checkout for 20% off.

    続きを読む 一部表示
    36 分
  • Ep 010. Psoriasis Part 1: Pathophysiology, Clinical Features, and Variants
    2026/09/28

    Send us Fan Mail

    Psoriasis High-Yield Review (Part 1): Epidemiology, Immunopathogenesis, Triggers, and Clinical Variants | The Derm Resident


    Hosts Dr. Jonny Hatch and Dr. Deven Curtis review psoriasis for residents, covering historical confusion with leprosy, prevalence (about 2% worldwide; higher in the US/Canada), bimodal onset (20–30 and 50–60), and systemic burden including psoriatic arthritis and comorbid metabolic, cardiovascular, and mood disease. They discuss genetics (notably HLA-Cw6 at PSORS1) and modern immunopathogenesis centered on the IL-23/Th17/IL-17 axis, including keratinocyte–immune “vicious cycle,” neutrophilic histology (Munro microabscesses, spongiform pustules of Kogoj), and TNF’s broad role. The episode reviews disease memory, Koebner phenomenon, triggers (strep, stress, HIV, hypocalcemia, pregnancy, key medications), lifestyle associations, classic plaque features and signs (Auspitz, Woronoff), PASI scoring, and variants including guttate, erythrodermic, and pustular psoriasis (IL36RN/DITRA; spesolimab), plus scalp, inverse, nail, and rare mucosal involvement.

    Contact: thedermresident.pod@gmail.com

    00:00 Show Intro and Disclaimer
    00:36 Psoriasis History Origins
    02:06 Epidemiology and Onset
    03:23 Systemic Burden Comorbidities
    04:22 Genetics and HLA CW6
    06:38 Modern Immune Model
    08:43 Trigger to T Cell Cascade
    12:02 Th17 Cytokines and Plaques
    15:08 IL 23 Th17 Axis Explained
    18:20 Histology Neutrophils and TNF
    20:48 Disease Memory and Koebner
    22:36 Triggers Infections Drugs Lifestyle
    27:19 Plaque Psoriasis Clinical Exam
    30:10 PASI Score Made Simple
    32:37 Guttate and Erythrodermic Types
    35:40 Pustular Variants and Genetics
    40:11 Special Sites Nails Mucosa
    42:14 Wrap Up and Part Two

    Free The Derm Resident sticker for US Residents only: https://forms.gle/5mwsAotTomxgDt7F7

    続きを読む 一部表示
    44 分
  • Ep 9. Generalized Pruritus, JAK Inhibitors, and Other Itch Treatments with Diego Ruiz Dasilva, MD
    2026/09/21

    Send us Fan Mail

    Chronic Pruritus Workup & Treatment Pearls (CPUO, Neuropathic Itch, Nemolizumab, JAKs) | The Derm Resident

    Contact: thedermresident.pod@gmail.com

    Dr. Jonny Hatch hosts Dr. Diego Da Silva, a chronic pruritus expert and host of Skin In the Game, to discuss a practical approach to itch. They outline an initial framework based on distribution (localized vs generalized), time course (with shorter duration and older age raising concern for malignancy), and morphology (primary lesions vs excoriations only). For localized itch without rash, they emphasize neuropathic etiologies (notalgia paresthetica, brachioradial pruritus, meralgia, dysesthesias), consider spine wear-and-tear, and discuss PT plus gabapentinoids and other neuromodulators. For generalized pruritus without rash, they review ROS for constitutional symptoms, recommend considering biopsy of “normal” itchy skin (e.g., CTCL, sarcoid), and suggest labs (CBC, CMP, TSH, A1C, SPEP/IFE, ferritin, vitamin D), chest X-ray, and BP testing/DIF. Treatment pearls include skincare, phototherapy, atopic-directed therapies (dupilumab, nemolizumab), JAK inhibitor counseling (noting shingles risk and “JAKne”), and empiric ivermectin for possible scabies; off-label options include low-dose naltrexone, dronabinol, and intranasal butorphanol, plus advice for residents to develop a niche and “declare” expertise.

    00:00 Show Introduction
    00:59 Why Itch Matters
    01:26 Finding a Niche
    04:44 First Steps in Pruritus
    07:00 Localized Itch Workup
    09:02 Neuropathic Itch Treatments
    11:32 Generalized Itch Workup
    14:32 Labs Imaging and Biopsy
    17:54 Treating CPUO Like Atopy
    21:49 Choosing First Biologic
    22:27 Nemolizumab Itch Breakthrough
    23:58 JAK Inhibitors Safety Reality
    26:08 Managing Shingles And Jackne
    28:05 Treating Jackne Options
    28:54 Derms As Real Doctors
    30:54 Low Dose Naltrexone Role
    32:15 Scabies And Empiric Ivermectin
    33:09 Off Label Itch Rescue Meds
    35:42 Advice And Podcast Wrap Up

    Free The Derm Resident sticker for US Residents only: https://forms.gle/5mwsAotTomxgDt7F7

    続きを読む 一部表示
    40 分
  • Ep 8. Atopic Dermatitis Management with Dr. Peter Lio Part 2 | Eczema Herpeticum/Kaposi’s Varicelliform Eruption, Infection Management, and the Atopic March
    2026/09/14

    Send us Fan Mail

    Atopic Dermatitis Cases & Board Pearls: Eczema Herpeticum/Kaposi’s Varicelliform Eruption, Infection Management, and the Atopic March | The Derm Resident

    Host dermatology resident Jonny Hatch and Dr. Peter Leo finish an atopic dermatitis episode with cases and board-focused pearls. They review recognition and urgent management of eczema herpeticum (crusted, punched-out lesions), emphasizing HSV PCR/culture, considering bacterial coinfection, empiric antivirals (valacyclovir/acyclovir) and when IV acyclovir/hospitalization is warranted, plus Tzanck smear and biopsy findings (three Ms). They discuss Kaposi’s varicelliform eruption etiologies including eczema coxsackium (supportive care, possible empiric antiviral while ruling out HSV, and onychomadesis) and a life-threatening eczema vaccinatum story. They cover the atopic march, transcutaneous sensitization, LEAP study implications, and why most eczema doesn’t improve with dietary restriction. Practical guidance includes treating impetiginized AD with drying compresses and topical mupirocin, limited oral antibiotics, updated views on bleach baths, bathing frequency, topical steroid potency by vehicle, dupilumab-associated conjunctivitis theories, IL-31-mediated itch, TSLP signaling, site-specific steroid absorption, and why JAK1 selectivity matters.

    00:00 Podcast Intro
    00:19 Eczema Herpeticum Case
    02:04 Testing and Swabs
    03:09 Empiric Treatment Plan
    04:05 When to Hospitalize
    05:27 Tzanck Smear Basics
    06:53 Eczema Coxsackium Overview
    07:33 Kaposi Varicelliform Story
    10:21 Differentiating Coxsackium
    11:32 Atopic March Explained
    13:56 Diet and Food Allergy Myths
    18:13 Bacterial Superinfection Case
    20:11 Topicals and Tea Compresses
    21:13 Bleach Baths Reality Check
    22:01 Topicals Over Orals
    23:50 Bleach Baths and Bathing
    27:23 Eczema Herpeticum Drill
    28:20 Steroid Potency Vehicles
    29:11 Dupilumab Eye Effects
    31:22 Itch Pathways Explained
    32:22 Eczema Coxsackium Care
    34:58 Atopic March TSLP
    36:42 Steroid Absorption Sites
    37:30 Genital Itch Strategy
    39:49 JAK STAT6 and Future
    41:41 Wrap Up and Thanks

    Free The Derm Resident sticker for US Residents only: https://forms.gle/5mwsAotTomxgDt7F7

    続きを読む 一部表示
    45 分
  • Ep 7. Atopic Dermatitis Management with Peter Lio, MD Part 1
    2026/09/07

    Send us Fan Mail

    Atopic Dermatitis Treatment Ladder: Moisturizers, Topical Steroids, Nonsteroidals, Biologics, and JAK Inhibitors (with Dr. Peter Lio) | The Derm Resident

    Contact: thedermresident.pod@gmail.com.

    Host dermatology resident Jonny Hatch interviews Dr. Peter Lio about atopic dermatitis treatment, emphasizing moisturizers (prescriptive product guidance, National Eczema Association Seal of Acceptance, ointments/petrolatum for stinging) and topical corticosteroid selection by potency, vehicle, and body site, with counseling on rare but important adverse effects and steroid stewardship. They distinguish tachyphylaxis from topical steroid withdrawal, noting evolving recognition and potential mechanistic clues. The episode reviews nonsteroidal topicals (tacrolimus/pimecrolimus counseling, black box warning context, stinging mitigation, crisaborole limitations, roflumilast benefits/rare diarrhea, topical ruxolitinib efficacy and boxed warning counseling), then escalates to systemic therapy with phototherapy, biologics (dupilumab, tralokinumab, lebrikizumab, nemolizumab), and oral JAK inhibitors (upadacitinib, abrocitinib) including risks and lab monitoring. They also discuss limited roles for antihistamines, the Dr. Aron regimen compound, and phage-lysin anti-staph products, and preview part two.

    00:00 Welcome and Guest Intro
    00:51 Moisturizers as Foundation
    02:45 Choosing Eczema Safe Products
    05:27 Ointments for Sensitive Skin
    07:07 Topical Steroid Ladder Basics
    08:43 Potency Picks and Stewardship
    11:18 Monitoring Steroid Side Effects
    12:45 Eyelids and Steroid Sparing
    14:19 Tachyphylaxis vs TSW
    17:23 Steroid Mechanism of Action
    18:51 Calcineurin Inhibitors Counseling
    22:42 Eucrisa and PDE4 Reality Check
    24:07 Roflumilast Practical Use
    25:59 Topical JAK Inhibitor Opzelura
    28:43 Placebo and Adherence
    29:14 When to Escalate Care
    29:41 Biologics Treatment Targets
    31:57 ADCT Control Scoring
    32:45 Insurance Documentation Tips
    33:24 Dupilumab Side Effects
    34:15 Managing Eye Symptoms
    36:13 Head and Neck Flares
    37:37 Switching Biologics Strategy
    39:32 Nemolizumab Itch Control
    40:00 Oral JAK Inhibitors Overview
    41:45 Black Box Risk Counseling
    44:36 Lab Monitoring Schedule
    46:13 Antihistamines Reality Check
    47:51 Aaron Regimen Compound
    51:53 Bacteriophage Spray Future
    53:42 Closing and Next Steps

    Free The Derm Resident sticker for US Residents only: https://forms.gle/5mwsAotTomxgDt7F7

    続きを読む 一部表示
    55 分
  • Ep 6. Atopic Dermatitis Pathophysiology, Clinical Features, Variants, and Biologics
    2026/08/31

    Send us Fan Mail

    Atopic Dermatitis High-Yield Review: Etymology, Diagnosis, Pathogenesis, Cytokines, Microbiome, Distribution, and Mimickers | The Derm Resident

    Email us: thedermresident.pod@gmail.com


    Hosts Dr. Jonny Hatch and Dr. Deven Curtis review high-yield atopic dermatitis (AD), covering its 1923 “atopos” etymology, clinical definition, and the atopic march (AD/food allergy in infancy, asthma in childhood, allergic rhinoconjunctivitis in adolescence). They outline AAD diagnostic criteria: pruritus, classic age-specific morphology/distribution, and chronicity, plus intrinsic (IgE-associated) vs non–IgE AD. Pathogenesis is framed as barrier dysfunction, immune dysregulation, and microbiome alteration, highlighting filaggrin’s role, transepidermal water loss, increased skin pH, and unchecked kallikrein proteases; Netherton syndrome (SPINK5/LEKTI) is discussed. They review Th2→Th1 evolution, key cytokines (IL-4/13 targeted by dupilumab; IL-13-only agents; IL-31 “itch cytokine” and nemolizumab), Staph aureus colonization and impetiginization, age-based distribution patterns, site variants and stigmata (Denny-Morgan lines, white dermatographism, keratosis pilaris, ichthyosis vulgaris), complications (ocular disease, eczema herpeticum with IV acyclovir on boards), quality-of-life impact, biopsy rationale (spongiotic dermatitis, rule out mycosis fungoides), and common mimickers and differentials including seb derm, scabies, contact dermatitis, immunodeficiencies, hypereosinophilia causes, nummular dermatitis, SCC in situ, dyshidrotic eczema, and asteatotic eczema.

    00:00 Welcome and Topic Setup
    00:31 Atopic Derm Name Origin
    01:59 What It Is and Atopic March
    04:41 Diagnosis Criteria Essentials
    06:13 IgE Types and Core Pathogenesis
    08:32 Barrier Breakdown and Filaggrin
    13:02 Proteases and Netherton Syndrome
    15:11 TH2 to TH1 Cytokine Shift
    18:09 Dupilumab IL4 IL13 Explained
    21:24 IL31 The Itch Cytokine
    23:57 Staph Aureus and Microbiome
    27:10 Age Based Distribution Infants
    27:53 Age Based Distribution
    29:32 Site Specific Variants
    31:18 Head Neck Dupixent
    31:58 Atopic Stigmata Signs
    34:24 Ichthyosis And KP
    36:09 Ocular Complications
    37:55 Eczema Herpeticum Urgency
    40:07 Quality Of Life Burden
    42:27 When To Biopsy
    45:18 Mimickers And Immunodeficiency
    49:31 Eosinophilia Differential
    50:22 Rapid Fire Dermatitis
    53:25 Episode Wrap Up

    Free The Derm Resident sticker for US Residents only: https://forms.gle/5mwsAotTomxgDt7F7

    続きを読む 一部表示
    55 分
  • Ep 5: Rosacea, Granulomatous Rosacea, Solid Facial Edema, Periorificial Dermatitis, etc. with Anuj Kunadia, MD
    2026/08/24

    Send us Fan Mail

    Rosacea High-Yield Review: Subtypes, Triggers, Treatment Ladder, and Key Differentials (with Dr. Anuj Kunadia) | The Derm Resident

    Contact us at: thedermresident.pod@gmail.com

    DermatoGraphix Discount Code (not an affiliate link): DERMNERDS30

    Link to Rosacea Sketches

    Dr. Jonny Hatch welcomes Dr. Anuj Kunadia, founder of DermatoGraphix, to review high-yield rosacea. They distinguish rosacea from acne by the absence of comedones and discuss subtypes: erythematotelangiectatic (erythema/telangiectasias, burning/stinging; often procedural treatment with PDL or IPL), papulopustular (topicals like azelaic acid, metronidazole, ivermectin; oral low-dose doxycycline; isotretinoin if refractory), phymatous (sebaceous hyperplasia/fibrosis; rhinophyma and other “phyma” sites; early isotretinoin vs surgical/laser debulking), and ocular (can precede skin findings; refer to ophthalmology and consider doxycycline). They cover pathogenesis including kallikrein-5/cathelicidin LL-37, Demodex association and ivermectin, common triggers, variants (granulomatous rosacea, rosacea fulminans, Morbihan disease), key differentials (seborrheic dermatitis, lupus), periorificial dermatitis management (stop steroids, pimecrolimus/doxycycline), and conclude with rapid-fire boards questions and an art-history rhinophyma example.

    00:00 Welcome and Setup
    00:19 Meet the Guest
    00:44 Dermatographics Origin
    01:52 Classic Rosacea Case
    02:30 Rosacea Basics
    03:08 Acne vs Rosacea
    04:21 Rosacea Subtypes
    04:49 ETR Features and Lasers
    05:58 Pathogenesis and Demodex
    08:55 Triggers and Photoprotection
    11:46 Phymatous Rosacea
    13:41 Ocular Rosacea Red Flags
    15:15 Rare Rosacea Variants
    19:34 Key Differentials
    23:19 Treatment Ladder Overview
    24:23 Topicals for Redness
    26:19 Papulopustular Treatments
    30:19 Procedures for Rhinophyma
    31:03 Periorificial Dermatitis
    34:29 Periorificial Treatment Plan
    35:47 Rapid Fire Boards Quiz
    41:01 Fun Fact and Wrap Up

    Free The Derm Resident sticker for US Residents only: https://forms.gle/5mwsAotTomxgDt7F7

    続きを読む 一部表示
    44 分
  • Ep 4. Acne Management with Dr. John Barbieri, MD
    2026/08/20

    Send us Fan Mail

    Acne & Rosacea Pearls with Dr. John Barbieri: Diagnosis, Antibiotics, Isotretinoin Dosing, and Pregnancy-Safe Options | The Derm Resident

    In this “Meet the Expert” episode of The Derm Resident, Dr. Jonny Hatch talks with acne and rosacea expert Dr. John Barbieri about practical, early-resident approaches to acne and common mimickers, emphasizing comedones as a key differentiator and reviewing clues for periorificial dermatitis, rosacea, and pityrosporum folliculitis. They discuss why “jawline acne” is not a strong predictor of PCOS/PMOS and why signs like irregular menses, hirsutism, and acanthosis nigricans are more informative. Dr. Barbieri outlines systemic treatment decision-making, favoring spironolactone over long-term antibiotics in many patients, and reviews antibiotic choices and resistance concerns. The conversation then covers isotretinoin timing, dosing to clinical endpoints, adjuncts to reduce flaring and side effects (loratadine, omega-3, L-carnitine), counseling on growth and mood risk, pregnancy-safe acne options, benzoyl peroxide/benzene concerns, rosacea redness treatment (oxymetazoline), and common trainee mistakes.

    00:00 Welcome and Guest Intro
    00:42 Acne Exam Basics
    01:08 Acne Mimickers
    02:36 History and PCOS Clues
    03:30 Jawline and Hormones
    05:26 Systemic Treatment Choices
    07:01 Low Dose Doxy Debate
    08:59 Antibiotics as Bridge
    10:59 Which Antibiotic to Pick
    13:35 Starting Isotretinoin (Accutane)
    15:46 Dosing and Endpoints
    17:32 Cumulative Dose Myths
    19:17 Higher Daily Dosing
    20:12 Antihistamine Add On
    21:09 Omega 3 For Dryness
    22:25 L Carnitine For Soreness
    23:42 Growth Stunting Myth
    24:33 Mood And Suicide Risk
    27:02 Acne In Pregnancy
    28:09 Topical Combo Strategies
    29:23 Benzoyl Peroxide and Benzene
    30:41 Resident Mistakes And Rosacea
    33:18 Rosacea Phenotype Approach
    34:52 Advice For New Residents
    35:30 Final Thanks And Wrap

    Free The Derm Resident sticker for US Residents only: https://forms.gle/5mwsAotTomxgDt7F7

    続きを読む 一部表示
    37 分